Glia, LLC

Asan Laboratories Company (Cayman), Limited

Other

Rhodes Technologies

Glla, LLC

Sunny Pharmtech Inc.

Chang, Wei-Wei

Slater, Kenneth

Richardson, Brenda

Sawyer, Kenneth

Wei-wei Chang

Kenneth I Sawyer

Yih-Lin Chung

Nam-Mew Pui

Kenneth C Slater

Brenda E Richardson

Scott M Connors

A method for rapid delivery of an active compound to innervate a cranial nerve of a subject. Also provided is a method for treating a disease or condition by topically applying a pharmaceutical composition to the face excluding the palpebral part of the eye, in an amount effective for treating the disease or condition.

Cranial delivery of pharmaceuticals

A method for treating a symptom of a neurodegenerative condition. The method includes topically administering a composition that contains a sex steroid or a cannabinoid or a mixture of both to the forehead, to an area of the outer ear of the subject not including the ear canal, or to both of these anatomical locations. The symptom treatable by the method is a motor symptom or a non-motor symptom.

Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves

The invention relates to compositions and methods for treating eye diseases and disorders. More specifically, the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.

Compositions and treatment for eye diseases and disorders

A method for treating radiotherapy- or chemotherapy-induced cognitive or emotional impairment by topically administering a cannabinoid. Also provided is a method for treating a tumor by topically administering a cannabinoid together with radiotherapy and/or chemotherapy.

Method for treating tumors with cannabinoids

A method of reducing the concentration of a chemical or drug substance in the blood plasma comprising titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together is seventy days or more.

Method and dosage regimens for eliminating a chemical substance in blood

A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.

Method for ameliorating pruritus

Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.

Treatment skin disorders

A method of reducing the concentration of a chemical or drug substance in the blood plasma that targets the same or similar receptors as the normal neurotransmitters in the central or peripheral nervous system includes titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together extends the method for seventy days or more.

Disclosed are compositions and methods for skincare, e.g., reducing skin wrinkles and for treating skin disorders.

Growing community of inventors

Boston, MA, United States of America

Wei-wei Chang